Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
01:42:52 20/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 54.56 USD | -0.30% |
|
+1.43% | +23.93% |
| 08-10 | Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date | MT |
| 08-10 | Novo Nordisk works to address FDA's findings at Indiana plant | FW |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 6,664 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 48.31% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 6,347 | 6,259 | 6,294 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 48.65% | -1.38% | 0.56% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -16.9x | -21.4x | -34.8x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 25.1x | 22.5x | 24.9x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 13.02x | 1x | 0.9x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 1,158x | 45x | 19x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 1,103x | 42.3x | 17.9x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -14.8x | -21.2x | -65.2x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -14.5x | -18x | -31.8x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -18.9x | -29.3x | -73.6x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.28% | -3.41% | -1.36% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.247 | -2.561 | -1.571 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 5.756 | 147.9 | 350.7 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -429 | -295.2 | -96.48 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -437.6 | -347.3 | -197.9 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -425.3 | -362.1 | -217.8 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -317.2 | -404.9 | -369.9 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 54.72 | 54.72 | 54.72 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 121,785 | - | - |
| Announcement Date | 7/3/22 | 7/3/23 | 19/3/24 | 27/2/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -16.85x | 1102.64x | -14.79x | -.--% | 6.66B | |
| 22.02x | 7.72x | 15.73x | 1.34% | 73.45B | |
| 36.15x | 9.26x | 28.49x | 0.04% | 62.99B | |
| -81.2x | 15.18x | -77.46x | -.--% | 28.05B | |
| 32.25x | 6.34x | 16.79x | -.--% | 25.42B | |
| -14.35x | 5.17x | -6.66x | -.--% | 23.3B | |
| 26.57x | 5.01x | 16.8x | -.--% | 19.45B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.16B | |
| -7088.72x | 40.96x | -262.55x | -.--% | 16.53B | |
| 16.43x | 4.87x | 11.36x | -.--% | 13.16B | |
| Average | -701.48x | 121.67x | -23.27x | 0.17% | 28.72B | |
| Weighted average by Cap. | -395.21x | 36.21x | -7.64x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
